EntryPoint Capital’s SELLAS Life Sciences SLS Stock Holding History

EntryPoint Capital’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-48,224	Closed	-$204K	–	949
2026 Q1	$204K	Buy	+48,224	New	+$216K	0.06%	635

Other funds holding SLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

EntryPoint Capital's SLS Position: Q2 2026 in Review

EntryPoint Capital sold out of SELLAS Life Sciences (SLS) in Q2 2026, closing a stake of 48,224 shares — an estimated $204K sold.

EntryPoint Capital first reported a position in SLS in Q1 2026 and held it in 1 quarter. The position peaked at $204K in Q1 2026. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

EntryPoint Capital reported no remaining SELLAS Life Sciences position as of Q2 2026 after selling out during the quarter.
EntryPoint Capital sold 48,224 SELLAS Life Sciences shares in Q2 2026, an estimated $204K.
EntryPoint Capital first reported a position in SELLAS Life Sciences in Q1 2026 and held it in 1 quarter.
EntryPoint Capital's SELLAS Life Sciences position peaked at $204K in Q1 2026.
192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.